10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute and committed to building a CLIA‑certified laboratory to support clinical deployment of its single‑cell and spatial biology technologies. The company said the partnerships will generate clinical evidence for diagnostic applications and speed translation from research to patient testing. 10x will collaborate on projects intended to generate data supporting the clinical validity and utility of single‑cell and spatial assays, and said the CLIA lab—targeted to open within about a year—will enable clinical offerings derived from those collaborations. Management framed the move as an expansion of 10x’s business model from research tools to clinical diagnostics, reflecting demand from physicians for validated clinical assays based on high‑resolution cellular profiling. Investors and customers will watch for regulatory strategies, reimbursement pathways and real‑world utility data. If successful, the effort could broaden 10x’s addressable market into diagnostics and create new revenue streams beyond instruments and reagents.